酒精性肝纤维化的血清标志物研究进展

张艳芳; 黄晶

doi:10.3969/j.issn.1001-5256.2018.03.041

酒精性肝纤维化的血清标志物研究进展

DOI: 10.3969/j.issn.1001-5256.2018.03.041

张艳芳,
黄晶

吉林大学白求恩第一医院检验科

详细信息

中图分类号: R446.1;R575.2
计量
- 文章访问数: 1938
- HTML全文浏览量: 21
- PDF下载量: 385
- 被引次数: 0
出版历程
- 出版日期: 2018-03-20

Research advances in serum markers for alcoholic liver fibrosis

摘要

摘要: 酒精性肝纤维化是由于长期过量摄入酒精使肝细胞发生炎症及坏死等改变,导致纤维结缔组织在肝内过度沉积而引发的一系列病理改变。实验室指标有助于助鉴别酒精性肝病,再进一步联合肝纤维化检验方法可诊断酒精性肝纤维化。其中肝纤维化诊断的"金标准"仍然是肝活组织检查,但因为其有创性,临床实践中开展受限。因此具有诊断价值的血清新型分子标志物近来不断被发现,且取得了较大突破;同时以综合多项临床生化指标、影像学为基础的肝纤维化非创伤性诊断预测模型对肝纤维化的诊疗也带来了新的希望。综述了近年来用血清标志物对酒精性肝纤维化非侵入诊断进行预测评估的研究进展。
- 肝硬化,酒精性 /
- 生物学标记 /
- 综述
Abstract: Alcoholic liver fibrosis is a series of pathological changes caused by excessive intrahepatic deposition of fibrous connective tissue due to hepatocyte inflammation and necrosis caused by excessive drinking. Laboratory markers help with the differentiation of alcoholic liver disease, and a combination of these markers and examination of liver fibrosis can be used for the diagnosis of alcoholic liver fibrosis. Liver biopsy remains the gold standard for the diagnosis of liver fibrosis, but its clinical application is limited by its invasiveness. Therefore, more and more new serum molecular markers with a diagnostic value have been identified in recent years, and great breakthroughs have been made. In addition, a noninvasive diagnostic and predictive model based on various biochemical parameters and imaging findings also brings new hope to the diagnosis and treatment of liver fibrosis. This article reviews the recent research advances in the noninvasive diagnosis of alcoholic liver fibrosis by serum markers.
- liver cirrhosis, alcoholic /
- biological markers /
- review

HTML全文

参考文献(31)

[1]HAO W, CHEN H, SU Z.China:alcohol today[J].Addiction, 2005, 100 (6) :737-741.

[2]LOMBARDI R, BUZZETTI E, ROCCARINA D, et al.Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease[J].World J Gastroenterol, 2015, 21 (39) :11044-11052.

[3]CHROSTEK L, PANASIUK A.Liver fibrosis markers in alcoholic liver disease[J].World J Gastroenterol, 2014, 20 (25) :8018-8023.

[4]SORBI D, BOYNTON J, LINDOR KD.The ratio of aspartate aminotransferase to alanine aminotransferase:potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease[J].Am J Gastroenterol, 1999, 94 (4) :1018-1022.

[5]WANG J, LI P, JIANG Z, et al.Diagnostic value of alcoholic liver disease (ALD) /nonalcoholic fatty liver disease (NAFLD) index combined withγ-glutamyl transferase in differentiating ALD and NAFLD[J].Korean J Intern Med, 2016, 31 (3) :479-487.

[6]LITTEN RZ, BRADLEY AM, MOSS HB.Alcohol biomarkers in applied settings:recent advances and future research opportunities[J].Alcohol Clin Exp Res, 2010, 34 (6) :955-967.

[7]SUEYOSHI S, SAWAI S, SATOH M, et al.Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease[J].World J Hepatol, 2016, 8 (36) :1610-1616.

[8]GOUGH G, HEATHERS L, PUCKETT D, et al.The utility of commonly used laboratory tests to screen for excessive alcohol use in clinical practice[J].Alcohol Clin Exp Res, 2015, 39 (8) :1493-1500.

[9]NIEMELAO.Biomarkers in alcoholism[J].Clin Chim Acta, 2007, 377 (1-2) :39-49.

[10]KOIVISTO H, HIETALA J, NIEMELAO.An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease[J].Am J Gastroenterol, 2007, 102 (4) :773-779.

[11]CAI WM, ZHANG BB, WENG HL, et al.The diagnostic value of eight serum indices for liver fibrosis[J].Chin J Hepatol, 2004, 12 (4) :219-222. (in Chinese) 蔡卫民, 张彬彬, 翁红雷, 等.八项肝纤维化血清标志物比较研究[J].中华肝脏病杂志, 2004, 12 (4) :219-222.

[12]SOWA JP, ATMACAO, KAHRAMAN A, et al.Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling[J].PLo S One, 2014, 9 (7) :e101444.

[13]STICKEL F, POESCHL G, SCHUPPAN D, et al.Serum hyaluronate correlates with histological progression in alcoholic liver disease[J].Eur J Gastroenterol Hepatol, 2003, 15 (9) :945-950.

[14]LIU T, WANG X, KARSDAL MA, et al.Molecular serum markers of liver fibrosis[J].Biomark Insights, 2012, 7:105-117.

[15]NØJGAARD C, JOHANSEN JS, CHRISTENSEN E, et al.Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease[J].J Hepatol, 2003, 39 (2) :179-186.

[16]SCHIAVON LL, CARVALHO-FILHO RJ, NARCISO-SCHIAVON JL, et al.YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection[J].Scand J Gastroenterol, 2010, 45 (5) :615-622.

[17]WEI H, LI B, ZHANG R, et al.Serum GP73, a marker for evaluating progression in patients with chronic HBV infections[J].PLo S One, 2013, 8 (2) :e53862.

[18]XU Z, LIU L, PAN X, et al.Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J].Medicine (Baltimore) , 2015, 94 (12) :e659.

[19]FENG ZG, CEN XH, YUN JM, et al.Diagnostic value of GP73 in alcoholic liver disease[J].Int J Lab Med, 2015, 36 (15) :2214-2215, 2217. (in Chinese) 冯志刚, 岑晓红, 云俊木, 等.GP73在酒精性肝病中的临床意义[J].国际检验医学杂志, 2015, 36 (15) :2214-2215, 2217.

[20]TOSHIMA T, SHIRABE K, IKEGAMI T, et al.A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA (+) -M2BP) , for assessing liver fibrosis[J].J Gastroenterol, 2015, 50 (1) :76-84.

[21]ZHOU D, WANG Y, ZHANG W, et al.WFA (+) -M2BP:a novel biomarker with diagnostic and therapeutic implications in liver diseases[J].Liver Int, 2016, 36 (4) :612.

[22]ZOU X, ZHU MY, YU DM, et al.Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection[J].Liver Int, 2017, 37 (1) :35-44.

[23]YANG YL, CUI YY, HU Y, et al.Role of the Mac-2 binding protein glycosylation isomer in diagnosis of chronic liver diseases[J].J Clin Hepatol, 2016, 32 (12) :2395-2398. (in Chinese) 杨以良, 崔园园, 胡月, 等.Mac-2结合蛋白糖基化异构体在慢性肝病诊断中的作用[J].临床肝胆病杂志, 2016, 32 (12) :2395-2398.

[24]HU GW.Research progress of serological detection index for liver fibrosis[J].Infect Dis Info, 2016, 29 (5) :315-317. (in Chinese) 胡高娃.肝纤维化血清学检测指标的研究进展[J].传染病信息, 2016, 29 (5) :315-317.

[25]CASTERA L.Hepatitis B:are non-invasive markers of liver fibrosis reliable?[J].Liver Int, 2014, 34 (Suppl 1) :91-96.

[26]NAVEAU S, RAYNARD B, RATZIU V, et al.Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease[J].Clin Gastroenterol Hepatol, 2005, 3 (2) :167-174.

[27]PARK MS, KIM SU, KIM BK, et al.Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B[J].Liver Int, 2015, 35 (2) :455-462.

[28]VOICAN CS, LOUVET A, TRABUT JB, et al.Transient elastography alone and in combination with Fibro Testfor the diagnosis of hepatic fibrosis in alcoholic liver disease[J].Liver Int, 2017, 37 (11) :1697-1705.

[29]CALES P, OBERTI F, MICHALAK S, et al.A novel panel of blood markers to assess the degree of liver fibrosis[J].Hepatology, 2005, 42 (6) :1373-1381.

[30]LOONG TC, WEI JL, LEUNG JC, et al.Application of the combined Fibro Meter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol, 2017, 32 (7) :1363-1369.

[31]TIAN HJ.Research progress in serological testing indicators of clinical examination for liver fibrosis[J].China Modern Med, 2013, 20 (9) :26-27. (in Chinese) 田红娟.肝纤维化血清学检测指标的研究进展[J].中国当代医药, 2013, 20 (9) :26-27.

施引文献

资源附件(0)

访问统计